These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 9388045)

  • 1. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
    Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes.
    Spinale FG; Holzgrefe HH; Mukherjee R; Webb ML; Hird RB; Cavallo MJ; Powell JR; Koster WH
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1082-94. PubMed ID: 9399980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
    Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
    Thomas CV; McDaniel GM; Holzgrefe HH; Mukherjee R; Hird RB; Walker JD; Hebbar L; Powell JR; Spinale FG
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):902-12. PubMed ID: 9869495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
    Weinberg EO; Lee MA; Weigner M; Lindpaintner K; Bishop SP; Benedict CR; Ho KK; Douglas PS; Chafizadeh E; Lorell BH
    Circulation; 1997 Mar; 95(6):1592-600. PubMed ID: 9118530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin AT1 receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition.
    Clair MJ; Krombach RS; Coker ML; Heslin TL; Kribbs SB; de Gasparo M; Spinale FG
    J Mol Cell Cardiol; 1998 Nov; 30(11):2355-64. PubMed ID: 9925371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action.
    Spinale FG; Iannini JP; Mukherjee R; Melton DM; de Gasparo M
    J Card Fail; 1998 Dec; 4(4):325-32. PubMed ID: 9924854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function.
    Spinale FG; Holzgrefe HH; Mukherjee R; Hird RB; Walker JD; Arnim-Barker A; Powell JR; Koster WH
    Circulation; 1995 Aug; 92(3):562-78. PubMed ID: 7634471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure.
    McMahon WS; Holzgrefe HH; Walker JD; Mukherjee R; Arthur SR; Cavallo MJ; Child MJ; Spinale FG
    J Am Coll Cardiol; 1996 Aug; 28(2):495-505. PubMed ID: 8800131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Clair MJ; Krombach RS; Hendrick JW; Houck WV; Hebbar L; Kribbs SB; Rios G; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
    J Card Fail; 1998 Dec; 4(4):311-23. PubMed ID: 9924853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Krombach RS; Clair MJ; Hendrick JW; Houck WV; Zellner JL; Kribbs SB; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
    Cardiovasc Res; 1998 Jun; 38(3):631-45. PubMed ID: 9747431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
    Ambrose J; Pribnow DG; Giraud GD; Perkins KD; Muldoon L; Greenberg BH
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):433-9. PubMed ID: 10069680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic angiotensin-converting enzyme inhibition on left ventricular and myocyte structure and function during recovery from chronic rapid pacing.
    Melton DM; Holzgrefe HH; Walker JD; Mukherjee R; Arthur SR; Antonaccio MJ; Koster WH; Spinale FG
    J Mol Cell Cardiol; 1997 Feb; 29(2):697-710. PubMed ID: 9140827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1.
    Vignier N; Le Corvoisier P; Blard C; Sambin L; Azibani F; Schlossarek S; Delcayre C; Carrier L; Hittinger L; Su JB
    Fundam Clin Pharmacol; 2014 Jun; 28(3):249-56. PubMed ID: 23600722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure.
    Cheng CP; Suzuki M; Ohte N; Ohno M; Wang ZM; Little WC
    Circ Res; 1996 May; 78(5):880-92. PubMed ID: 8620609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
    Müller-Brunotte R; Edner M; Malmqvist K; Kahan T
    J Hypertens; 2005 Mar; 23(3):633-40. PubMed ID: 15716707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade.
    Hayashida W; Donckier J; Van Mechelen H; Charlier AA; Pouleur H
    Cardiovasc Res; 1997 Jan; 33(1):54-62. PubMed ID: 9059528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
    Richer C; Fornes P; Cazaubon C; Domergue V; Nisato D; Giudicelli JF
    Cardiovasc Res; 1999 Jan; 41(1):100-8. PubMed ID: 10325957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction.
    Hongo M; Sentianin EM; Tanaka N; Mao L; McKirnan MD; Clark RG; Won W; Chien KR; Ross J
    J Card Fail; 1998 Sep; 4(3):213-24. PubMed ID: 9754592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.